Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Open accessThe DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases represent nowadays one of the major health problems. Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not entirely clear what triggers this phenomenon and what allows its progression. Nevertheless, it is accepted that neurodegeneration is a consequence of several detrimental processes, such as protein aggregation, oxidative stress, and neuroinflammation, finally resulting in the loss of neuronal functions. Starting from these evidences, there has been a wide search for novel agents able to address more than a single event at the same time, the so‐called multitarget‐directed ligands (MTDLs). These compounds originated from the combination of different pharmacophoric elements which endowed them with the ability to interfere with different enzymatic and/or receptor systems, or to exert neuroprotective effects by modulating proteins and metal homeostasis. MTDLs have been the focus of the latest strategies to discover a new treatment for Alzheimer’s disease (AD), which is considered the most common form of dementia characterized by neurodegeneration and cognitive dysfunctions. This review is aimed at collecting the latest and most interesting target combinations for the treatment of AD, with a detailed discussion on new agents with favorable in vitro properties and on optimized structures that have already been assessed in vivo in animal models of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given the multifactorial nature of AD523”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [523]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“Amongst the latter, the Fatty Acid Amide Hydrolase (FAAH) was originally identified as the enzyme responsible for AEA hydrolysis [96] while the Monoacylglycerol Lipase (MGL) plays a pivotal role in the regulation of 2-AG levels [97].”
BackgroundBrown, R. H., & Al-Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,125
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989 · cited 1×
“that catalyzes the removal of acetyl groups from the lysine residues of both histone and nonhistone proteins [116].”
BackgroundTherapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768 · cited 1×
“It is involved in several cellular processes and signaling pathways and its dysregulation occurs in the development of different disorders [35].”
BackgroundHDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644 · cited 1×
“In particular, HDAC2 and HDAC3 have a critical role in controlling memory-related genes [120], while dampening HDAC6 activity enhances pTAU and Aβ clearance [121– 122].”
BackgroundAlzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551 · cited 1×
“ACh plays a pivotal role in cognitive processes, and disruptions in its neurotransmission can influence all the aspects of cognition and behavior, not only in AD but also in other age-related forms of dementia [27].”
BackgroundHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009 · cited 1×
“Recently, the activation of NMDARs has been linked to AD-related synaptic dysfunctions [64] and the NMDAR noncompetitive antagonist Memantine has been approved as symptomatologic treatment for moderate to severe AD [65].”
Background
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Superoxide dismutase as multipotent therapeutic antioxidant enzyme: Role in human diseases
Saxena, P., Selvaraj, K., Khare, S. K., & Chaudhary, N. (2022) · Biotechnology Letters · doi:10.1007/s10529-021-03200-3 · Cited by 160
“In addition to the above mentioned, there are many other symptoms of Alzheimer’s disease are trouble in locating the right phrase, vision/spatial problems, and impaired reasoning or judgment (Maramai et al. 2020).”
BackgroundNiewiadomska, G., Niewiadomski, W., Steczkowska, M., & Gasiorowska, A. (2021) · Life · doi:10.3390/life11010028 · Cited by 131
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., De Strooper, B., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 131
“Just as treating multiple pathways and molecular networks in other diseases, such as cancer and human immunodeficiency virus-1 has improved outcome [13–15], a similar network medicine approach can be envisaged for AD [10, 13, 16, 17].”
BackgroundRehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2021) · Biomolecules · doi:10.3390/biom11050767 · Cited by 120
Kumar, N., Kumar, V., Anand, P., Kumar, V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 105
β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer’s Disease Therapy
Beato, A., Gori, A., Boucherle, B., Peuchmaur, M., & Haudecoeur, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01887 · Cited by 88
Pupyshev, A. B., Klyushnik, T. P., Akopyan, A. A., Singh, S. K., & Tikhonova, M. A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106373 · Cited by 87
Pentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210408123807 · Cited by 73
“this highly desirable goal, as for example novel chemical derivatives [132] or complementary strategies with nutraceuticals [6].”
Iqbal, D., Rehman, M. T., Dukhyil, A. B., Rizvi, S. M. D., Ajmi, M. F. A., Alshehri, B., Banawas, S., Khan, M. S., Alturaiki, W., & Alsaweed, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090937 · Cited by 67
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Sharma, A., Rudrawar, S., Bharate, S. B., & Jadhav, H. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00630e · Cited by 70
Makarian, M., Gonzalez, M., Salvador, S. M., Lorzadeh, S., Hudson, P. K., & Pecic, S. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131425 · Cited by 61
Kareem, R. T., Abedinifar, F., Mahmood, E. A., Ebadi, A. G., Rajabi, F., & Vessally, E. (2021) · RSC Advances · doi:10.1039/d1ra03718h · Cited by 67
Askarani, H. K., Iraji, A., Rastegari, A., Bukhari, S. N. A., Firuzi, O., Akbarzadeh, T., & Saeedi, M. (2020) · BMC Chemistry · doi:10.1186/s13065-020-00715-0 · Cited by 60
Lipoic acid. Kinetics and pluripotent biological properties and derivatives
Theodosis‐Nobelos, P., Papagiouvannis, G., Tziona, P., & Rekka, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06643-z · Cited by 55
Iqbal, D., Alsaweed, M., Jamal, Q. M. S., Asad, M. R., Rizvi, S. M. D., Rizvi, M. R., Albadrani, H. M., Hamed, M., Jahan, S., & Alyenbaawi, H. (2023) · Biomolecules · doi:10.3390/biom13111613 · Cited by 57
Hafez, D. E., Dubiel, M., Spada, G. L., Catto, M., Reiner‐Link, D., Syu, Y.-T., Abdel‐Halim, M., Hwang, T., Stark, H., & Abadi, A. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2175821 · Cited by 50
“Recently, evaluation of riluzole in a clinical trial for AD was reported.29 Inspired by the similarity in the pharmacophoric features of the H3R antagonists and AChE inhibitors, the activity of the synthesised compounds on AChE enzyme to reach multitarget inhibition was tested.14 The dual-acting compounds (3b, 3h, 3j,…”
BackgroundInfluentialGuo, M., Wang, Z., Zhou, X., Yu, C., Wu, J., Yu, L., Mi, J., Ren, F., Law, B. Y. K., Pan, H., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156928 · Cited by 52
Asghar, S., Mushtaq, N., Ahmed, A., Anwar, L., Munawar, R., & Akhtar, S. (2024) · Molecules · doi:10.3390/molecules29020490 · Cited by 48
“By combining e ff ective pharmacophoric groups within a single molecule, MTDLs combining effective pharmacophoric groups within a single molecule, MTDLs can provide superior therapeutic outcomes compared to single-target compounds with high affinity for one or a few targets [23–27].”
BackgroundLiu, T., Chen, S., Du, J., Xing, S., Li, R., & Li, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113973 · Cited by 48
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Sampietro, A., Pérez-Areales, F. J., Martínez, P., Arce, E. M., Galdeano, C., & Muñoz‐Torrero, D. (2022) · Pharmaceuticals · doi:10.3390/ph15050545 · Cited by 50
“Even if some HDAC-hitting multitarget compounds have been described, the occurrence of HDAC-based combinations is almost anecdotic, so they should be explored in much more detail, as recently suggested, for example, for the combinations HDACs/GSK-3β and HDACs/PDEs [53].”
BackgroundSheng, J., Zhang, S., Wu, L., Kumar, G., Liao, Y., K., P. G., & Fan, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1019187 · Cited by 49
“Hybridization of the Pyrazolopyrimidinone skeleton with Rivastigmine yielded another series of potential PDE9A inhibitors using a similar strategy (Maramai et al., 2022).”
BackgroundMethodInfluentialBortolami, M., Pandolfi, F., Tudino, V., Messore, A., Madia, V. N., de Vita, D., di Santo, R., Costi, R., Romeo, I., Alcaro, S., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00485 · Cited by 34
“− 21 In our previous studies, we synthesized and in vitro evaluated new series of dual binding site ChEIs, characterized by two small aromatic moieties separated by various functionalized linkers, some of which resulted in nanomolar mixed or uncompetitive inhibitors of both AChE and BChE, able to…”
InfluentialZinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease
Li, Y., Lin, S., Gu, Z., Chen, L., & He, B. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129015 · Cited by 36
Vediappan, P., Arumugam, M., & Natarajan, R. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099282836231212064925 · Cited by 34
Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases
Katsoulaki, E.-E., Dimopoulos, D., & Hadjipavlou‐Litina, D. (2025) · Pharmaceuticals · doi:10.3390/ph18060831 · Cited by 35
Singh, Y. P., Kumar, N., Priya, K., Chauhan, B. S., Shankar, G., Kumar, S., Singh, G. K., Srikrishna, S., Garg, P., Singh, G., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00443 · Cited by 32
Бачурин, С. О., Aksinenko, A. Y., Махаева, Г. Ф., & Shevtsova, E. F. (2023) · Russian Chemical Bulletin · doi:10.1007/s11172-023-3718-0 · Cited by 34
Wu, W., Wen, Z.-Y., Qian, J., Zou, J., Liu, S., Yang, S., Qin, T., Yang, Q., Liu, Y.-H., Liu, W., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132498 · Cited by 30
Bardakkaya, M., Kılıç, B., Sağkan, R. I., Aksakal, F., Shakila, S., & Doğruer, D. S. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300054 · Cited by 30
On the relationships between epilepsy, sleep, and Alzheimer’s disease: A narrative review
Hanke, J.-M., Schindler, K. A., & Seiler, A. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108609 · Cited by 29
“A few examples are the inhibition of proteins involved in the process of tau hyperphosphorylation (GSK3-inhibitors) [74,147] or of Aß aggregation (BACE-1-inhibitors) [147,148] or monoclonal antibodies targeting Aß aggregates [148,149].”
BackgroundAdvances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
Sánchez, J. D., Alcántara, A. R., González, J. F., & Sánchez-Montero, J. M. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2264766 · Cited by 26
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suarez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02465-9 · Cited by 26
Iqbal, D., Rehman, M. T., Alajmi, M. F., Alsaweed, M., Jamal, Q. M. S., Alasiry, S. M., Albaker, A. B., Hamed, M., Kamal, M., & Albadrani, H. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040622 · Cited by 28
Berrino, E., Carradori, S., Carta, F., Melfi, F., Gallorini, M., Poli, G., Tuccinardi, T., Fernández‐Bolaños, J. G., López, Ó., Petzer, J. P., et al. (2023) · Antioxidants · doi:10.3390/antiox12122044 · Cited by 27
Nadeem, M. S., Khan, J. A., & Rashid, U. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.102 · Cited by 25
Nuthakki, V. K., Choudhary, S., Reddy, C. N., Bhatt, S., Jamwal, A., Jotshi, A., Raghuvanshi, R., Sharma, A., Thakur, S., Jadhav, H. R., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00030 · Cited by 25
Godyń, J., Zaręba, P., Łażewska, D., Stary, D., Reiner‐Link, D., Frank, A., Latacz, G., Mogilski, S., Kaleta, M., Doroż-Płonka, A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105129 · Cited by 21
Anupama, K. P., Olakkaran, S., Antony, A., Raghu, S. V., & Gurushankara, H. P. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.02.011 · Cited by 25
Purgatorio, R., Gambacorta, N., de Candia, M., Catto, M., Rullo, M., Pisani, L., Nicolotti, O., & Altomare, C. (2021) · Molecules · doi:10.3390/molecules26175208 · Cited by 20
“Starting from seminal papers on the therapeutic potential of multi-target directed ligands (MTDLs) as disease-modifying agents [19,20], many efforts have been reported to identify new MTDLs, mostly by conjugating AChE inhibitors (donepezil and/or the withdrawn drug tacrine) with a molecular moiety able to interact wit…”
BackgroundChromenone: An emerging scaffold in anti-Alzheimer drug discovery
Agarwal, U., Verma, S. K., & Tonk, R. K. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129912 · Cited by 21
Belardo, C., Alessio, N., Pagano, M., Dominicis, E. D., Infantino, R., Perrone, M., Iannotta, M., Galderisi, U., Rinaldi, B., Scuteri, D., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108978 · Cited by 19
Personalized Management and Treatment of Alzheimer’s Disease
Cacabelos, R., Naidoo, V., Martínez-Iglesias, O. A., Corzo, L., Cacabelos, N., Pego, R., & Carril, J. C. (2022) · Life · doi:10.3390/life12030460 · Cited by 24
“Over 2000 new AChEIs, some of them with dual inhibitory activity on acetylcholinesterase and butyrylcholinesterase, have been identified, as well as over 150 multi-target drugs [101,102].”
BackgroundPharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Cacabelos, R., Naidoo, V., Martínez-Iglesias, O. A., Corzo, L., Cacabelos, N., Pego, R., & Carril, J. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_13 · Cited by 19
Recent Advances in Enzyme Inhibition: A Pharmacological Review
Singh, K., Bhushan, B., Mittal, N., Kushwaha, A., Raikwar, C. K., Sharma, A. K., Chanchal, D. K., Kumar, S., & Agrawal, M. (2023) · Current Enzyme Inhibition · doi:10.2174/0115734080271639231030093152 · Cited by 22
BACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer’s disease
Arya, R., Jain, S., Paliwal, S., Madan, K., Sharma, S. K., Mishra, A., Tiwari, P. K., & Kadiri, S. K. (2024) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_192_24 · Cited by 20
Mateev, E. (2022) · FARMACIA · doi:10.31925/farmacia.2022.2.21 · Cited by 17
Anupama, K. P., Antony, A., Olakkaran, S., Raghu, S. V., & Gurushankara, H. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02964-7 · Cited by 16
“Since AD is a multifactorial disease [9], it is essential to develop multitargeted therapeutic drugs for its treatment.”
BackgroundMostefa, N., Djebli, N., Khánh, P. N., Ha, N. X., Anh, H. T. N., Ha, V. T., Hương, T. T., Anh, D. V., & Cường, N. M. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202201051 · Cited by 16
Grover, P., Rohilla, S., Bhardwaj, M., Mehta, L., & Malhotra, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230406084315 · Cited by 16
What is the gold standard model for Alzheimer’s disease drug discovery and development?
Cacabelos, R., Carrera, I., Martínez-Iglesias, O. A., Cacabelos, N., & Naidoo, V. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1960502 · Cited by 16
Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators
Morales, P., Muller, C., Jagerovic, N., & Reggio, P. H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.841190 · Cited by 17
“As a consequence, a number of research studies have highlighted the importance of multipletarget strategies for the treatment of multifactorial disorders such as pain and neurodegenerative diseases (Cheong et al., 2019; Gontijo et al., 2019; Maramai et al., 2020).”
BackgroundKhan, M. S., Khan, Z., Jabir, N. R., Mehan, S., Suhail, M., Zaidi, S. K., Zughaibi, T. A., Abid, M., & Tabrez, S. S. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04351-w · Cited by 13
Design and Synthesis of Hsp90 Inhibitors with B‐Raf and PDHK1 Multi‐Target Activity
Pinzi, L., Foschi, F., Christodoulou, M. S., Passarella, D., & Rastelli, G. (2021) · ChemistryOpen · doi:10.1002/open.202100131 · Cited by 12
Halder, D., Das, S., Jeyaprakash, R. S., & Joseph, A. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2158136 · Cited by 15
“To improve overall pharmacotherapeu-tics, research should focused on increasing encapsulation, bioavailability, permeation, solubility and decreasing the toxicity of the drug (Maramai et al., 2020).”
BackgroundPaolino, M., de Candia, M., Purgatorio, R., Catto, M., Saletti, M., Tondo, A. R., Nicolotti, O., Cappelli, A., Brizzi, A., Mugnaini, C., et al. (2023) · Molecules · doi:10.3390/molecules28155857 · Cited by 12
Maciejewska, K., Czarnecka, K., Kręcisz, P., Niedziałek, D., Wieczorek, G., Skibiński, R., & Szymański, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115876 · Cited by 12
“Although the cholinergic hypothesis loses importance in the pathogenesis of Alzheimer’s disease in favor of β-amyloid, cholinergic-based strategies remain the most common approach in the treatment of AD and other forms of dementia [15].”
BackgroundPaolino, M., Rullo, M., Maramai, S., de Candia, M., Pisani, L., Catto, M., Mugnaini, C., Brizzi, A., Cappelli, A., Olivucci, M., et al. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00042c · Cited by 11
Self-citationThakur, A., Rana, M., Vanjani, S., Liou, K.-C., Taliyan, R., Nepali, K., & Yang, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70047 · Cited by 12
Genetic architecture of hippocampus subfields volumes in Alzheimer’s disease
Cai, J., Xiong, W., Wang, X., Tan, H., & Database, T. A. D. N. I. (. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14110 · Cited by 10
Aboushady, Y., Gabr, M. T., ElHady, A. K., Salah, M., Abadi, A., Wilms, G., Becker, W. B., Abdel‐Halim, M., & Engel, M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00475 · Cited by 10
Self-citationRecent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer’s Disease
Yamalı, C., & Dönmez, Ş. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221201145141 · Cited by 10
A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study
Pereira, A. M., de Souza, C. F. M., Álvarez-Córdoba, M., Reche-López, D., & Sánchez-Alcázar, J. A. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03453-x · Cited by 9
“Regarding this, multitarget therapy promises to address the multifaceted complexity of neurodegenerative diseases [67, 68].”
Kandeil, M. A., Mohammed, E. T., Ibrahim, M. A., Radi, R. A., Fouad, A. G., Abdel‐Razik, A. H., Khalıl, F., & Sabry, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05241-5 · Cited by 9
Ja’afaru, S. C., Uzairu, A., Mishra, V. K., Sallau, M. S., Ibrahim, M. T., & Dubey, A. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00281-6 · Cited by 8
“For validation of 1 3 113 affinity and activity, aiming to facilitate improved interac - tions and inhibition of the target's function (Maramai et al. 2020 ).”
Ma, X., Yang, T., Liu, L., Peng, X., Qian, F., & Tang, F.-R. (2023) · Biomolecules · doi:10.3390/biom13050754 · Cited by 12
“Although efforts have been made to reveal the pathogenesis that leads to neurodegenerative diseases, the detailed mechanism underlying the structural and functional changes of neurons is still unclear [8].”
BackgroundGodyń, J., Zaręba, P., Stary, D., Kaleta, M., Kuder, K., Latacz, G., Mogilski, S., Reiner‐Link, D., Frank, A., Doroż-Płonka, A., et al. (2022) · Molecules · doi:10.3390/molecules28010238 · Cited by 8
“Multitarget therapeutic strategies based on multitargetdirected ligands (MTDLs) seem to fulfill such requirements [20,21].”
BackgroundQuinazoline derivatives as novel bacterial sphingomyelinase enzyme inhibitors
Öztürk, O., Oyardı, Ö., & Dündar, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108079 · Cited by 7
Tran, T., Doan, D.-N.-H., Cao, T., Tran, T., & Tran, T.-D. (2025) · RSC Advances · doi:10.1039/d5ra02267c · Cited by 7
Jarné‐Ferrer, J., Pallàs, M., Griñán‐Ferré, C., & Bellver‐Sanchís, A. (2025) · Cells · doi:10.3390/cells14120934 · Cited by 7
“Due to the multifaceted nature of the disease, the absence of a single-target therapy capable of halting or reversing its progression has emerged as a significant challenge [22–24].”
Álvarez-Córdoba, M., Talaverón-Rey, M., Povea-Cabello, S., Cilleros-Holgado, P., Gómez-Fernández, D., Piñero-Pérez, R., Reche-López, D., Munuera-Cabeza, M., Suárez-Carrillo, A., Romero-González, A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101359 · Cited by 9
“Therefore, multitargeted therapies with antioxidant and mitochondrial-stimulating compounds may address the multifactorial and complex nature of these diseases more effectively [204,205].”
BackgroundBarbosa, D. B., de Oliveira, L. M. G., Mendes, G. O., Costa, D. B., de Oliveira, T. A., da Silva, M. P., Damázio, L. C. M., Maia, E. H. B., Falkoski, D. L., Marra, I. F. D. S., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c07084 · Cited by 6
Chhabra, N., Matore, B. W., Murmu, A., Kumar, A., Gawande, P., Singh, J., & Roy, P. P. (2025) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2025.2579695 · Cited by 6
“…(COX-2), c-Jun N-terminal kinase 3 (JNK3/MAPK10), dopamine D2 receptor, dopamine D3 receptor and N-methyl-D-aspartate (NMDA) receptor were identified and highlighted for the multi-target (MT) strategy [16] through reported literature studies [15,17] and our previous findings [16,18,19].”
Benetik, S. F., Proj, M., Knez, D., Košak, U., Meden, A., Krajšek, K., Pišlar, A. H., Horvat, S., Švajger, U., Tešić, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00933 · Cited by 6
Vilela, A. F. L., dos Reis, V. E. N., & Cardoso, C. L. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.708374 · Cited by 6
“Indeed, existing treatments for AD have shortcomings or result in failure, so researchers have been devoted to changing drug design strategies to investigate multitarget-directed ligands (Hughes et al., 2016; de Freitas Silva et al., 2018; Maramai et al., 2020; Uddin et al., 2021).”
BackgroundPrema, V., Meena, A., & Ramalakshmi, N. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249300784240430110628 · Cited by 6
Ameliorative effect of walnut oil against cognitive impairment in alzheimers type dementia in rodent
Ma, C., Zhang, L., Wang, L., Huang, Q., Deng, Q., Huang, F., & Xu, J. (2024) · Oil Crop Science · doi:10.1016/j.ocsci.2024.09.003 · Cited by 5
Al‐Rifai, N., Al-Khalileh, N. M., Zahra, J. A., El‐Barghouthi, M. I., & Darras, F. H. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2281264 · Cited by 5
Ekoh, O. C., Timothy, R. A., Asogwa, F. C., Gber, T. E., Ikeuba, A. I., Ugwu, D. I., & Louis, H. (2024) · Chemistry Africa · doi:10.1007/s42250-024-00908-3 · Cited by 5
Petkova-Kirova, P. S., Anastassova, N., Minchev, B., Uzunova, D. N., Grigorova, V., Tsvetanova, E. R., Georgieva, A. P., Alexandrova, A., Stefanova, M. O., Yancheva, D. Y., et al. (2024) · Molecules · doi:10.3390/molecules29235711 · Cited by 5
Azusada, T., Baybay, E., Chi, J., Dole, P., González, N., Jaramillo, E., Nguyen, T., Pivaral, A., Rodriguez, G., Zavala, J., et al. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101226 · Cited by 5
Abdildinova, A., Kim, Y.-C., Lee, G., Park, W., Cho, H., & Gong, Y. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131417 · Cited by 5
Sardar, A., Hussain, R., Khan, S. A., Iqbal, T., Sarfraz, H., Khan, A. A., Binsaleh, A. Y., Al‐Hoshani, N., Alwethaynani, M. S., Anajirih, N., et al. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416525501042 · Cited by 8
Lee, Y., Han, S., Lee, J., Cho, Y. E., Kim, J., Jeon, Y., Cho, H., Yoo, H., Byun, Y., Kim, T. K., et al. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01562-0 · Cited by 4
“These multifactorial features highlight the complexity of AD and underscore the need for novel therapeutic strategies that can target multiple aspects of the disease simultaneously (Ibrahim et al.2019; Maramai et al. 2020; Zhang et al.2024).”
Elbermawy, Y., El-Desouky, S., Arafa, R. K., Elfarrash, S., & Bassiouny, A. R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05534-9 · Cited by 5
“This perspective highlights the need for multitarget therapeutic strategies capable of addressing the complex molecular landscape of AD [54, 55].”
Poggialini, F., Governa, P., Vagaggini, C., Maramai, S., Lamponi, S., Mugnaini, C., Brizzi, A., Purgatorio, R., de Candia, M., Catto, M., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107066 · Cited by 4
Self-citationMaramai, S., Saletti, M., Paolino, M., Giuliani, G., Cazzola, J., Spaiardi, P., Talpo, F., Frosini, M., Pifferi, A., Ballarotto, M., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117872 · Cited by 3
Self-citationMasum, M. H. U., Lokman, S. M., Parvin, R., Rahman, M. S., Chowdhury, E. H., Chamonara, K., Chowdhury, S., Mahdeen, A. A., & Khatun, M. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326219 · Cited by 4
Yu, L., Gao, C., Wang, Z., Zhang, R., Chen, Y., & Zhenli, M. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220531144809 · Cited by 3
Elbadawi, M. M., Elgazar, A. A., Hefny, A. A., Abdulla, M., Traiki, T. B., Roshdy, E., Al-Sanea, M. M., Abe, M., Eldehna, W. M., Rao, P. P. N., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70046 · Cited by 2
Computational Multi-target Drug Design
Guruprasad, L., Saxena, S., Banerjee, A., & Ganesh, B. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_28 · Cited by 3
Rekha, D., Kumari, P. V. K., Thummala, U. K., Reddy, Y. D., Prasanth, D., & Kumar, P. P. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00778-6 · Cited by 3
Castelló-Guillen, A., Garrido-Reig, M., Caplliure‐Llopis, J., Vega‐Bello, M. J., Almela, C., & Ortí, J. E. D. L. R. (2026) · Pharmaceuticals · doi:10.3390/ph19091405 · Cited by 3
“This widening therapeutic gap underscores the urgent need for pleiotropic interventions capable of addressing the convergent molecular mechanisms underlying neurodegeneration, which remain insufficiently targeted by current single-mechanism strategies [4,5].”
Network-Pharmacology and Central Nervous System Drug Development
Talevi, A. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_9 · Cited by 2
Pal, M., Maurya, A., Shukla, R., Siddiqui, Z., Pathak, S. K., Srivastava, R., Shukla, V. K., Prasad, O., & Sinha, L. (2024) · Molecular Simulation · doi:10.1080/08927022.2024.2397463 · Cited by 1
“Multiple factors contribute to the development of Alzheimer ’ s disease, including damage to cholinergic nerves, reduced acetylcholine levels, mitochondrial dysfunction, oxidative stress, the build-up of amyloid β (A β ) plaques, imbalances in metal ions and more [5 – 10].”
Kittibunchakul, S., Inthachat, W., Sahasakul, Y., Boonjoong, T., Suttisansanee, U., Thangsiri, S., Pitchakarn, P., Temviriyanukul, P., & Kemsawasd, V. (2026) · Future Foods · doi:10.1016/j.fufo.2026.100966 · Cited by 1
Shah, D., Patel, A., & Patel, A. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2649001 · Cited by 1
Zhou, J., & Chen, M. (2026) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad3020019 · Cited by 2
“The high concordance between multi-target candidates and synergistic pairs suggests that well-designed MTDLs can function as intrinsic combinations, offering pharmacokinetic and adherence advantages [83,84].”
Metadata
- Authors
- Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S.
- Affiliations
- University of Siena (IT)
- Conservatoire National des Arts et Métiers (FR)
- Stanford Medicine (US)
- Helmholtz Institute for Pharmaceutical Research Saarland (DE)
- Corresponding author
- Maramai, Samuele
- Yahiaoui, Samir
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 2020
- Issue
- 1
- Pages
- 5120230-5120230
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC7354643
- OpenAlex
- W3039786831
- Cited by
- 121
- References
- 145
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 20 · 2023: 17 · 2022: 29 · 2021: 22 · 2020: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-sa)
- Use Siena air (University of Siena) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, multi-target-directed ligands, multi-target therapy, neurodegeneration, protein aggregation, oxidative stress, neuroinflammation, neuroprotection, metal homeostasis, drug discovery, animal models of dementia
- MeSH terms
- Alzheimer Disease, Animals, Humans, Ligands, Oxidative Stress, Neuroprotective Agents, Molecular Targeted Therapy, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.